This database contains 472 studies, archived under the term: "Pharmaceutical Interventions"
Click here to filter this large number of results.
Levodopa use and sleep in patients with dementia with Lewy bodies
Sleep disturbance and excessive daytime somnolence (EDS) are features of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) that may be influenced by dopamine replacement therapy. The effect of levodopa on sleep and EDS in DLB is unknown and unclear in PD. The aim of this study is to determine if levodopa treatment alters […]
A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia
Mizukami, Katsuyoshi,
Asada, Takashi,
Kinoshita, Toru,
Tanaka, Katsuaki,
Sonohara, Kazuki,
Nakai, Ryuhei,
Yamaguchi, Kiyoshi,
Hanyu, Haruo,
Kanaya, Kiyoshi,
Takao, Tetsuya,
Okada, Masakatsu,
Kudo, Sumio,
Kotoku, Hayato,
Iwakiri, Masahiko,
Kurita, Hirofumi,
Miyamura, Toshihiro,
Kawasaki, Yosuke,
Omori, Koji,
Shiozaki, Kazumasa,
Odawara, Toshinari,
Suzuki, Tatsuya,
Yamada, Shizuru,
Nakamura, Youichi,
Toba, Kenji
The effectiveness and safety of yokukansan (TJ-54), a traditional Japanese medicine (kampo) for the treatment of the behavioural and psychological symptoms of dementia (BPSD), were evaluated in 106 patients diagnosed as having Alzheimer’s disease (AD) (including mixed-type dementia) or dementia with Lewy bodies. Patients were randomly assigned to group A (TJ-54 treatment in period I […]
Long-term rivastigmine treatment in a routine clinical setting
Objective: The aim of the study was to observe the effects of long-term rivastigmine treatment in patients with mild to moderate Alzheimer’s disease (AD) in a routine clinical setting.; Methods: This was a prospective, open-label, observational, multicentre, non-randomized study. Outcome measures included the Mini Mental State Examination (MMSE), the Clinician’s Interview-Based Impression of Change (CIBIC) […]
Donepezil delays progression to AD in MCI subjects with depressive symptoms
Lu, P. H.,
Edland, S. D.,
Teng, E.,
Tingus, K.,
Petersen, R. C.,
Cummings, J. L.
Objective: To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship.; Methods: The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer’s Disease Cooperative Study drug trial […]
Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental
Lloret, Ana,
Badía, Mari-Carmen,
Mora, Nancy J.,
Pallardó, Federico V.,
Alonso, Maria-Dolores,
Viña, Jose
There is controversy as to whether vitamin E is beneficial in Alzheimer’s disease (AD). In this study, we tested if vitamin E prevents oxidative stress and loss of cognition in AD. Fifty-seven AD patients were recruited and divided in two groups: placebo or treated with 800 IU of vitamin E per day for six months. […]
Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease
Leyhe, Thomas,
Eschweiler, Gerhard W.,
Stransky, Elke,
Gasser, Thomas,
Annas, Peter,
Basun, Hans,
Laske, Christoph
Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer’s disease (AD). In experimental investigations, lithium induces brain-derived neurotrophic factor (BDNF). Recent studies have found a decrease of BDNF in the serum and brains of AD patients with potentially consecutive lack of neurotrophic support. We assessed the influence of […]
Efficacy and safety of memantine in Lewy body dementia
Lewy body dementia (LBD) is a progressive brain disease manifest as dementia and parkinsonism, along with psychotic and autonomic disorders. Although studies in recent years have demonstrated the positive effects of cholinesterase inhibitors in LBD, the search for therapeutic agents with other mechanisms of action remains relevant. An open, controlled, 16-week study was performed with […]
Randomized controlled trial of memantine in dementia associated with Parkinson’s disease
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson’s disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 […]